Arch Therapeutics Inc (ARTH)

[Polyphemus]

ARTH presentation did seem to include some important information, through both statements and omissions. Some key takaways were:

*AC5 does not form by covalent bonding and is not 'adhesive'. Translation: AC5 does not have property of staying where MD applied AC5. This would make it very hard for an 'internbal' application to be safe or effective.

*Still no reason provided for lack of marketing in the US of a device purported to be valuable and competitive after the ARTH received premarket clearance from FDA in Dec. 2018.

*AC5 was compared in "Competitive Matric" to generic products for the treatment of wounds - not compared to any approved absorbable hemostats for the treatment of internal bleeding that would not cease spontaneously. No brand name products were mentioned in the matrix, so statements are without significance and are not meaningfully verifiable.

*ARTH is still struggling to find any entity willing to buy and distribute (resell) AC5.

*ARTH has "identified" inhternal applications for AC5 technology, but provided no real evidence of prooof of principle or development.

*171 Million shares in curent float, with more dilution likely to come in order to provide cash. For what purpose?